Form 4: X4 Pharmaceuticals Executive Increases Stake Through Employee Stock Purchase Plan

Mark Baldry, Chief Commercial Officer of X4 Pharmaceuticals, acquired 1,032 shares of common stock through the company's employee stock purchase plan at $2.482 per share.

Summary

• On May 16, 2025, Mark Baldry, the Chief Commercial Officer of X4 Pharmaceuticals, purchased 1,032 shares of common stock.
• The purchase was made through the company's Amended and Restated 2017 Employee Stock Purchase Plan.
• The price per share was $2.482.
• Following the transaction, Baldry directly owns 25,337 shares of X4 Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction related to an employee stock purchase plan. It's neither overwhelmingly positive nor negative.

Positives

• An executive's participation in the employee stock purchase plan can be seen as a positive signal, indicating confidence in the company's future.

Industry Context

This transaction is a routine disclosure related to insider trading and is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company executive.

Key Dates

Keywords

X4 Pharmaceuticals, Mark Baldry, Employee Stock Purchase Plan, Common Stock, Beneficial Ownership, Form 4, Securities